SILEXION THERAPEUTICS CORP (SLXN) Stock Income Statement
USA - NASDAQ:SLXN - KYG1281K1307 - Common Stock
3.93 USD
+0.16 (+4.24%)
3.84 USD
-0.09 (-2.29%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 13.87M | 12.57M | 6.05M | 1.11M | 770.00K | |||
| Research and Development | 5.70M | 5.82M | 3.71M | N/A | N/A | |||
| Selling, General, and Administrative Expenses | 8.16M | 6.73M | 928.00K | 1.23M | 940.00K | |||
| Operating Income | -13.87M | -12.57M | -6.05M | -1.11M | -770.00K | |||
| Interest Income/Expense | 874.00K | 904.00K | 978.40K | 1.69M | 10.00K | |||
| Other Income/Expense | -60.00K | -59.00K | -9.00K | N/A | N/A | |||
| Non Recurring Items | N/A | -4.78M | N/A | N/A | N/A | |||
| Income Before Taxes | -17.84M | -16.51M | -5.08M | 580.00K | -760.00K | |||
| Income Tax | 6.00K | 10.00K | 32.00K | N/A | N/A | |||
| Net Income | -17.84M | -16.52M | -5.11M | 580.00K | -760.00K | |||
| EBITDA | -13.84M | -12.55M | -6.00M | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -165.54 | -134.03 | -70.59 | 8.01 | -0.06 | |||
| Non GAAP EPS | -350.07 | N/A | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD